ReviewNature reviews. Clinical oncology2015
Management of locally advanced breast cancer-perspectives and future directions.
Review in Nature reviews. Clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 93 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Comparative efficacy and safety of eribulin versus paclitaxel in breast cancer: a systematic review and meta-analysis.Future oncology (London, England) · 2024Pooled it
- Pooled it
- Pooled it
- ER-Targeted PET for Initial Staging and Suspected Recurrence in ER-Positive Breast Cancer.JAMA network open · 2024Trial
- A phase 2 study of capecitabine and concomitant radiation in women with advanced breast cancer.International journal of radiation oncology, biology, physics · 2017Trial
- Weekly taxane-anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial.Chinese journal of cancer · 2017Trial
- Multi-Parametric Ultrasound Radiomic Kinetics with Machine Learning Ensemble for Early Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Baseline and Early-Delta Quantitative Ultrasound Radiomics for Predicting Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer.Journal of clinical medicine · 2026Article
- Biochemical alterations in endocrine and inflammatory pathways following breast cancer surgery: Laboratory evidence and clinical implications.Journal of medical biochemistry · 2026Article
- Development and validation of explainable machine learning models for the prediction of survival in patients with M1 breast cancer.Gland surgery · 2026Article
- Article
- Longitudinal contrast-enhanced cone beam breast computed tomography for monitoring treatment response in breast cancer neoadjuvant therapy: a comprehensive assessment.Breast cancer research : BCR · 2025Article
- Current perspectives and global trends of nanotechnology in advanced breast cancer: a bibliometric and visualized analysis.Discover oncology · 2025Article
- Article
- Review
- Rare diagnosis of locally advanced triple‑negative breast cancer with paraneoplastic dermatomyositis: A case report and literature review.Oncology letters · 2025Article
- Prediction of Chemotherapy Response in Locally Advanced Breast Cancer Patients at Pre-Treatment Using CT Textural Features and Machine Learning: Comparison of Feature Selection Methods.Tomography (Ann Arbor, Mich.) · 2025Article
- Network pharmacology unveils the intricate molecular landscape of Chrysin in breast cancer therapeutics.Discover oncology · 2025Article
- Abemaciclib treatment patterns and outcome in HR+/HER2- locally advanced or metastatic breast cancer: a real-world study from Kuwait and Lebanon.Frontiers in oncology · 2025Article
- Exploratory Research of Intraductal Chemotherapy to Control the Focal Breast Lesion of Breast Cancer.Breast cancer (Dove Medical Press) · 2025Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Locally advanced breast cancer (LABC) constitutes a heterogeneous entity that includes advanced-stage primary tumours, cancers with extensive nodal involvement and inflammatory breast carcinomas. Although the definition of LABC can be broadened to include some large operable breast tumours, we use this term to strictly refer to inoperable cancers that are included in the above-mentioned categories. The prognosis of such tumours is often unfavourable; despite aggressive treatment, many patients eventually develop distant metastases and die from the disease. Advances in systemic therapy, including radiation treatment, surgical techniques and the development of new targeted agents have significantly improved clinical outcomes for patients with this disease. Notwithstanding these advances, LABC remains an important clinical problem, particularly in developing countries and those without widely adapted breast cancer awareness programmes. The optimal management of LABC requires a multidisciplinary approach, a well-coordinated treatment schedule and close cooperation between medical, surgical and radiation oncologists. In this Review, we discuss the current state of the art and possible future treatment strategies for patients with LABC.
Indexed as
Identifiers
25668732What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.